Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

3DCardiacHTS

Financiado

Bringing 3D cardiac tissues to high throughput for drug discovery screens

1. Cardiovascular disease is the number 1 cause of death worldwide. Novel cardiovascular drugs have a high failure rate of 91% in clinical trials. This failure rate is due to lack of proper cardiac models used to find new drugs. D... ver más

30/11/2025

RIVER BIOMEDICS

1M€

Presupuesto del proyecto: 1M€

Líder del proyecto

RIVER BIOMEDICS B.V. No se ha especificado una descripción o un objeto social para esta compañía.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-10-26

HORIZON-EIC-2022-TRANSITIONOPEN-01: EIC Transition Open 2022 Expected Impact:At the end of the EIC Transition project, it should be ready for the next stage, whi...

I+D

Cerrada hace 2 años

0% 100% 100%

1 Participantes

RIVER BIOMEDICS

1.46M€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

HEART2BEAT Advanced human models of the heart to understand cardiovascu... 3M€ Cerrado

ACQUIRE Assessing cardiac Contractility and Quantification of Underl... 150K€ Cerrado

3DVasCMD Development of novel 3D vascularized cardiac models to inves... 1M€ Cerrado

CPP2021-008396 SISTEMA MICROFLUIDICO PARA APLICACIONES EN TEJIDO EN UN CHIP 378K€ Cerrado

SYNEBIO High-throughput combinatory drugs testing on in vitro 3D cel... 150K€ Cerrado

MUSCLEGUY A novel muscle disorders 3D in vitro system for drug screeni... 150K€ Cerrado

Duración del proyecto: 37 meses Fecha Inicio: 2022-10-26
Fecha Fin: 2025-11-30

Líder del proyecto

RIVER BIOMEDICS B.V. No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 1M€

Descripción del proyecto 1. Cardiovascular disease is the number 1 cause of death worldwide. Novel cardiovascular drugs have a high failure rate of 91% in clinical trials. This failure rate is due to lack of proper cardiac models used to find new drugs. Drug discovery studies rely mainly on 2D culture models, which have insufficient predictive value of the human heart. A new in vitro 3D model has been developed by assembling human cardiomyocytes into a three-dimensional strip configuration (3D cardiac strip) that better mimics the native heart tissue. However, this system is not compatible with the high throughput setting needed to perform drug discovery screens. River BioMedics has found a unique solution to miniaturize the human 3D cardiac strips and use them in a high-throughput assay. We combine two innovative technologies: human induced pluripotent stem cell (hiPSC)-cardiac cells and microfluidic systems. The Open-TOP microfluidic technology developed in the group of Prof. v.d. Berg from the University of Twente enables the culturing hundreds of culture chambers automatically and consistently, which is key in high throughput screens. This technology will enable the production and culture of 3D cardiac strips in large numbers, bringing 3D vitro models into a high throughput scale. The end users of this technology are pharma companies performing drug discovery activities and CROs providing drug discovery services. For commercialization of 3DCardiacHTS we plan to partner with an end-user and assess their requirements for the use of such high throughput technology, with the intention of securing their partnership at the end of the project In parallel we will discuss the various partnering options with identified potential Pharma partners and/or CROs the best financial deal structure for partnership on 3DCardiacHTS and consequently validate the best business model to pursue the commercialization of 3DCardiacHTS.

Conecta tu I+D

Entra hoy

¿Olvide mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores